Showing results (1791-1800 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|May 22, 2020
Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor ModelsNikki Phanhthilath, Sara Hakim, Catherine Su, et al.
Investigational New Drugs|May 22, 2020
ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinibSho Sakamoto, Kazuhiro Sato, Yuri Takita, et al.
Investigational New Drugs|April 28, 2021
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor modelsFanyi Meng, Yinshuang Chen, Man Yang, et al.
Investigational New Drugs|November 10, 2022
Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)Kun Qian, Qi-Rui Chen, Ming He, et al.
Investigational New Drugs|September 9, 2021
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancerXue Zhou, Ning Wang, Yuefeng Zhang, et al.
Investigational New Drugs|January 9, 2026
Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemiaJieqiong Liu, Wei Sun, Chunjiang Wang
Investigational New Drugs|November 10, 2025
Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins MutationsKavita Sangwan, Gaurav Agarwal
Investigational New Drugs|May 22, 2025
Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibitionBenkun Liu, Fucheng Zhou, Bowen Shi, et al.
Investigational New Drugs|June 4, 2025
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumorsNai-Jung Chiang, Li-Yuan Bai, I-Wei Ho, et al.
Investigational New Drugs|June 5, 2025
Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasisJian Xiao, Zhi Xia, Zhu Wu, et al.
Pageof 372